Bilovol, O.Knyazkova, I.Golovacheva, V.Kuzminova, N.Barbashova, V.Molodan, D.Bogun, N.2022-11-262022-11-262022Effect of eplerenone on serum level of soluble growth-stimulating receptor expressed by gene 2 in patients with arterial hypertension / O. M. Bilovol, I. I. Knyazkova, V. O. Golovacheva, N. V. Kuzminova, V. O. Barbashova, D. V. Molodan, M. V. Bogun // World of Medicine and Biology. – 2022. – № 3 (81). – P. 26–31. – DOI: 10.26724/2079-8334-2022-3-81-26-31.https://repo.knmu.edu.ua/handle/123456789/31155The purpose of the work was to study the dynamics of diastolic function parameters, the content of the soluble growth-stimulating receptor expressed by gene 2 (sST2) and the N-terminal fragment of the brain natriuretic propeptide (NT-proBNP) in the blood of patients with hypertension, when eplerenone is added to antihypertensive therapy. In patients with stage 2 arterial hypertension, addition of eplerenone to antihypertensive therapy contributes to a more pronounced decrease of blood pressure measured by patients during self-monitoring; during daily monitoring compared to antihypertensive therapy. The inclusion of the selective aldosterone mineralocorticoid receptor antagonist eplerenone in the complex therapy of patients with stage 2 arterial hypertension has a pronounced positive effect on the structural and geometric indicators of the myocardium, parameters of the diastolic function of the left ventricle, as well as the content of sST2 and NT-proBNP in the blood serum, along with good tolerability.enhypertensioneplerenonediastolic dysfunctionechocardiographysoluble growth-stimulating receptor expressed by gene 2,N-terminal fragment of brain natriuretic propeptideArticle